FGF basic/FGF2/bFGF Antibody - Azide and BSA Free

Immunohistochemistry: FGF basic/FGF2/bFGF Antibody - Azide and BSA Free [NB600-1536] -

High VEGF-A and FGF2 labeling levels in an orthotopic OS mouse model and in human lung metastasis specimens: (A) U2-OS tumor image at 5 weeks and (B) anti-VEGF-A immunolabeling. Representative images of primary OS tumors in mice and nearby bone. The labeling pattern was mainly cytoplasmic; however, nuclear labeling was also noticed. Images were obtained under a ×40 magnification. Scale bar denotes 50 um. (C) Quantitative analysis of immunolabeled area (tumor/bone ratio) of primary OS tumors in mice normalized to nearby bone. Primary OS tumors exhibit significantly higher VEGF-A levels compared to control bone; *** p < 0.001. (D) FGF2 immunolabeling. Representative images of primary OS tumors in mice and nearby bone. Images were obtained under ×40 magnification. Scale bar denotes 50 um. (E) Quantitative analysis of immunolabeled area (tumor/bone ratio) of primary OS tumors in mice normalized to nearby bone. Primary OS tumors exhibit significantly higher FGF2 levels compared to control bone; ** p < 0.01. (F) Representative anti-VEGF-A and anti-FGF2 immunolabeling of human metastatic OS and non-metastatic OS patient specimens. Images showing nuclear labeling pattern. Microscope images were obtained under ×40 magnification. Scale bar denotes 50 um. (G) Quantitative analysis of immunolabeled area (1/um2) in metastatic vs. non-metastatic human OS specimens. Higher levels of VEGF-A (primary, N = 7; metastasis, N = 8) and FGF2 (primary, N = 6; metastasis, N = 14) were obtained in metastatic samples compared to primary tumors; * p < 0.05, and **** p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/2072-6694/15/6/1818), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: FGF basic/FGF2/bFGF Antibody - Azide and BSA Free [NB600-1536] -

High VEGF-A and FGF2 labeling levels in an orthotopic OS mouse model and in human lung metastasis specimens: (A) U2-OS tumor image at 5 weeks and (B) anti-VEGF-A immunolabeling. Representative images of primary OS tumors in mice and nearby bone. The labeling pattern was mainly cytoplasmic; however, nuclear labeling was also noticed. Images were obtained under a ×40 magnification. Scale bar denotes 50 um. (C) Quantitative analysis of immunolabeled area (tumor/bone ratio) of primary OS tumors in mice normalized to nearby bone. Primary OS tumors exhibit significantly higher VEGF-A levels compared to control bone; *** p < 0.001. (D) FGF2 immunolabeling. Representative images of primary OS tumors in mice and nearby bone. Images were obtained under ×40 magnification. Scale bar denotes 50 um. (E) Quantitative analysis of immunolabeled area (tumor/bone ratio) of primary OS tumors in mice normalized to nearby bone. Primary OS tumors exhibit significantly higher FGF2 levels compared to control bone; ** p < 0.01. (F) Representative anti-VEGF-A and anti-FGF2 immunolabeling of human metastatic OS and non-metastatic OS patient specimens. Images showing nuclear labeling pattern. Microscope images were obtained under ×40 magnification. Scale bar denotes 50 um. (G) Quantitative analysis of immunolabeled area (1/um2) in metastatic vs. non-metastatic human OS specimens. Higher levels of VEGF-A (primary, N = 7; metastasis, N = 8) and FGF2 (primary, N = 6; metastasis, N = 14) were obtained in metastatic samples compared to primary tumors; * p < 0.05, and **** p < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://www.mdpi.com/2072-6694/15/6/1818), licensed under a CC-BY license. Not internally tested by Novus Biologicals.